Alligator Bioscience AB completes rights issue, raising SEK 58.8 million to fund wind-down and strategic refocus on HLX22 financial interest.
Amount Raised
SEK58.8 Million
Round Type
Venture
LundBiotechnologyDescription
Alligator Bioscience AB completed a rights issue that was subscribed to approximately 17.1 percent, with guarantee commitments covering a further 29.7 percent, raising SEK 58.8 million before issue costs. The company used proceeds to repay SEK 19 million in bridge loans. Alligator is refocusing on its financial interest in the HER2-targeting antibody programme HLX22, which is in global Phase 3 development. The company is winding down its own drug development operations, with the reduced cost base expected to be fully in effect from the second quarter of 2027.
Who to call at Alligator Bioscience, and when
A new round usually means Alligator Bioscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alligator Bioscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alligator Bioscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alligator Bioscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alligator Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Alligator Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.